Closeup of a hand holding a model brain

Chambers-Grundy Center for Transformative Neuroscience News

The Chambers-Grundy Center for Transformative Neuroscience provides an academic platform for research and learning opportunities regarding the study of drug development for Alzheimer's disease and other brain disorders. It includes a clinical trials observatory for tracking new treatments, trial designs, and biomarkers in clinical trials for neurodegenerative disorders.

Current Transformative Neuroscience News

woman in white labcoat using computer
UNLV History |

Amanda Osse is the first recipient of the award named in honor of Nathan Lindsay, who passed away after a 15-year battle with Alzheimer's disease.

Students at Pida Plaza on the first day of classes (Josh Hawkins, UNLV).
Campus News |

A roundup of prominent news stories highlighting university pride, research, and community collaboration.

Closeup of a hand holding a model brain
Research |

Annual review of current Alzheimer’s clinical trials reveals trends in design, therapies, outcomes, and funding surrounding work to develop new treatments.
 

Dancers with the U.N.L.V. Ewalu Club
Campus News |

A collection of news stories highlighting research wins, expert insights, and academic achievement.

detail shot of lab equipment
Campus News |

UNLV expert Dr. Jeffrey Cummings explains how a new lab expands UNLV's neuroscience research capabilities.

people doing research
Research |

UNLV researchers made international headlines this year with their discoveries. Here's a roundup of some of our top stories of 2021.

Transformative Neuroscience In The News

MedPage Today

Most ARIA cases are mild, but some have been fatal

MedPage Today

Recently approved disease-modifying treatments for Alzheimer's disease have created a sudden demand, but these and other drugs in the pipeline are not for all patients with clinical Alzheimer's symptoms, experts said.

MedPage Today

Looking ahead to 2024 and beyond: "There is so much more to be done"

NeurologyLive

Over the past year, the field has experienced another significant leap of growth, powered by advances in translational research and capped off by the approval of lecanemab (Leqembi; Eisai), the first traditionally approved therapy in nearly two decades.

Daily Mail

After decades of failed trials, ineffective drugs and billions of dollars spent, a new frontier of shots offer a glimmer of hope for current and future sufferers of the cruel condition that affects 5.8million Americans.

NetworkNewsWire

The positive results are expected to form the basis for further development of Lomecel-B as a potential treatment for mild AD

Transformative Neuroscience Experts

An expert in behavioral neuroscience with concentrations in Alzheimer's disease and schizophrenia.
A renowned expert on Alzheimer's Disease and other neurodegenerative disorders. 

Recent Transformative Neuroscience Accomplishments

Dr. Jeffrey Cummings (Integrated Health Sciences), research professor in the Department of Brain Health and director of the Chambers-Grundy Center for Transformative Neuroscience, will serve as a keynote speaker during the Clinical Trials in Alzheimer's Disease conference in Boston, Massachusetts, on Oct. 24. Cummings has also been a co-…
Research professor and director Jeffrey Cummings, (Brain Health, Chambers-Grundy Center for Transformative Neuroscience) and director Jamie Schwartz (Industry and Business Engagement, Economic Development) were awarded a $1.5 million INNOVATOR grant from the National Institute of Aging (NIA). This five-year grant will help the…
Dr. Jeff Cummings (Brain Health) published "Trial of Pimavanserin in Dementia-Related Psychosis" in the New England Journal of Medicine.       
Jeffrey Cummings (Brain Health) co-authored a paper published in Nature on developing the ATX(N) classification, a system for recognizing biomarkers in blood that indicate the presence in the brain of plaques and tangles characteristic of Alzheimer’s disease.  ATX(N) advances allow researchers to diagnose Alzheimer’s disease without…
Dr. Jeffrey Cummings (Brain Health) recently published an article outlining a novel method for determining whether Alzheimer’s drug treatments in clinical trials are ready to move on to the next phase. The paper, “Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach,” was published in The Journal of…
Dr. Jeffrey Cummings (Brain Health) recently published an article, “The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs," in the Journal of Prevention of Alzheimer’s Disease. The somewhat provocative findings note that despite the trend toward prevention trials becoming more likely (in part because trials…